Ultra-low dose rituximab in pemphigus: a single centre experience.

Rituximab is a monoclonal antibody which binds to the CD-20 antigen expressed on B-cell lymphocytes (1). It has shown efficacy in the treatment of pemphigus by depleting the B-cells to which it binds reducing production of destructive antibodies (2, 3).